Total Revenue Increased 15%; Advertising Revenue Increased 18%
WebMD Achieves Strong Traffic Growth: Unique Monthly Users Grow 24%
to 59.8 Million and Quarterly Page Views Grow 31% to 1.4 Billion
NEW YORK, July 30 /PRNewswire-FirstCall/ -- WebMD Health Corp.
(NASDAQ: WBMD) today announced financial results for the three
months ended June 30, 2009. "We are pleased to deliver strong
results again this quarter. WebMD's advertising revenue grew by 18%
as we see continuing demand from both pharmaceutical as well as
consumer products companies in the health and wellness markets,"
said Wayne Gattinella, President and CEO. "I am enthusiastic about
the momentum we are gaining in our business as our customers are
shifting more of their marketing spend online." Financial Summary
Revenue for the second quarter was $98.6 million, compared to $86.0
million in the prior year period, an increase of 15%. Earnings
before interest, taxes, non-cash and other items ("Adjusted
EBITDA") for the second quarter was $23.2 million or $0.40 per
share, compared to $18.4 million or $0.31 per share in the prior
year period, an increase of 26%. Income from continuing operations
for the second quarter was $7.0 million or $0.12 per share,
compared to $5.7 million or $0.10 per share in the prior year
period. Loss from discontinued operations was $(4.9) million in the
second quarter, compared to income from discontinued operations of
$663 thousand in the prior year. Net income for the second quarter
was $2.1 million or $0.04 per share, compared to $6.4 million or
$0.11 per share in the prior year period. WebMD's financial results
present Little Blue Book, its print directory business, as
discontinued operations for current and prior periods reflecting
the ongoing process to divest Little Blue Book. The loss from
discontinued operations and net income for the second quarter of
2009 include a non-cash, after-tax impairment charge of $5 million
or $0.09 per share related to the carrying value of WebMD's Little
Blue Book physician directory business. WebMD had approximately
$373 million in cash and investments at June 30, 2009. Operating
Highlights Public portal advertising and sponsorship revenue was
$76.0 million for the second quarter, compared to $64.1 million in
the prior year period, an increase of 18%. Traffic to the WebMD
Health Network continued to grow strongly, reaching an average of
59.8 million unique users per month and total traffic of 1.4
billion page views during the second quarter, increases of 24% and
31%, respectively, from a year ago. In the second quarter, 1.6
million continuing medical education (CME) programs were completed
on the WebMD Professional Network, an increase of 25% from the
prior year period. Private portal services revenue was $22.6
million for the second quarter compared to $21.9 million in the
prior year period, an increase of 4%. The base of large employers
and health plans utilizing WebMD's private Health and Benefits
portals during the second quarter was 137 as compared to 123 a year
ago. During the quarter, WebMD launched integrated platform
services for Blue Cross and Blue Shield of Florida, Inc. Merger
with HLTH Corporation As previously announced, HLTH and WebMD
entered into a definitive merger agreement on June 17, 2009. On
July 10, 2009, WebMD filed a Registration Statement with the SEC
containing a preliminary joint proxy statement/prospectus relating
to the merger. HLTH and WebMD have scheduled stockholders meetings
for September 25, 2009 to seek the necessary stockholder approvals.
Financial Guidance WebMD reaffirmed its financial guidance for 2009
today and narrowed the ranges for its anticipated revenue and
Adjusted EBITDA by raising the low end of those ranges. For 2009,
WebMD expects: -- Total revenue to be $420 million to $440 million,
an increase of 12% to 18% over 2008; -- Adjusted EBITDA to be $110
million to $120 million, an increase of 17% to 28% over 2008; --
Income from continuing operations to be approximately $31 million
to $41 million, or $0.51 to $0.66 per share, an increase of 21% to
58% over 2008. For the quarter ending September 30, 2009, WebMD
expects revenue to be in the range of $109 million to $112 million
with Adjusted EBITDA representing approximately 28% of revenue.
These amounts represent growth of approximately 18% to 19% in
public portal advertising and sponsorship revenue and 4% in private
portal services revenue. Income from continuing operations is
estimated to be 10% of revenue for the third quarter of 2009.
Additional detail is provided in a schedule attached to this
release. Analyst and Investor Conference Call As previously
announced, WebMD will hold a conference call with investors and
analysts to discuss its second quarter results at 4:45 pm (eastern)
today. The call can be accessed at http://www.wbmd.com/ (in the
Investor Relations section). A replay of the audio webcast will be
available at the same web address. About WebMD WebMD Health Corp.
(NASDAQ:WBMD) is the leading provider of health information
services, serving consumers, physicians, healthcare professionals,
employers and health plans through our public and private online
portals and health-focused publications. WebMD Health Corp. is a
subsidiary of HLTH Corporation (NASDAQ:HLTH). The WebMD Health
Network includes WebMD Health, Medscape, MedicineNet, eMedicine,
eMedicine Health, RxList and theHeart.org. All statements contained
in this press release and the related analyst and investor
conference call, other than statements of historical fact, are
forward-looking statements, including those regarding: guidance on
WebMD's future financial results and other projections or measures
of WebMD's future performance; market opportunities and WebMD's
ability to capitalize on them; the benefits expected from new or
updated products or services and from other potential sources of
additional revenue; expectations regarding the market for WebMD's
investments in auction rate securities (ARS); the merger
transaction between HLTH and WebMD (the "Merger Transaction"); and
the potential sale of Porex by HLTH (the "Potential Sale
Transaction"). These statements speak only as of the date of this
press release, are based on our current plans and expectations, and
involve risks and uncertainties that could cause actual future
events or results to be different than those described in or
implied by such forward-looking statements. These risks and
uncertainties include those relating to: market acceptance of
WebMD's products and services; WebMD's relationships with customers
and strategic partners; changes in the markets for ARS; and changes
in economic, political or regulatory conditions or other trends
affecting the healthcare, Internet and information technology
industries. Further information about these matters can be found in
our Securities and Exchange Commission filings. In addition, there
can be no assurances regarding: whether HLTH and WebMD will be able
to complete the Merger Transaction or as to the timing of such
transaction; or whether HLTH will be able to complete the Potential
Sale Transaction or as to the timing or terms of such transaction.
Except as required by applicable law or regulation, we do not
undertake any obligation to update our forward-looking statements
to reflect future events or circumstances. This press release, and
the accompanying tables, include both financial measures in
accordance with accounting principles generally accepted in the
United States of America, or GAAP, as well as certain non-GAAP
financial measures. The tables attached to this press release
include reconciliations of these non-GAAP financial measures to
GAAP financial measures. In addition, an "Explanation of Non-GAAP
Financial Measures" is attached to this press release as Annex A.
WebMD , Medscape , eMedicine , MedicineNet , RxList , Subimo ,
Medsite , The Little Blue Book and Summex , are trademarks of WebMD
Health Corp. or its subsidiaries. WEBMD HEALTH CORP. CONSOLIDATED
STATEMENTS OF OPERATIONS (In thousands, except per share data,
unaudited) Three Months Six Months Ended Ended June 30, June 30,
-------- -------- 2009 2008 2009 2008 ------- ------- -------
------- Revenue $98,631 $86,004 $188,895 $166,654 Cost of
operations 39,229 31,968 75,794 62,895 Sales and marketing 26,797
24,898 54,358 50,047 General and administrative 15,139 14,211
29,865 27,691 Depreciation and amortization 6,804 7,087 13,741
13,759 Interest income 924 2,350 1,899 5,803 Impairment of auction
rate securities - - - 27,406 ------- ------- ------- ------- Income
(loss) from continuing operations before income tax provision
11,586 10,190 17,036 (9,341) Income tax provision 4,636 4,501 6,847
7,933 ------- ------- ------- ------- Income (loss) from continuing
operations 6,950 5,689 10,189 (17,274) (Loss) income from
discontinued operations, net of tax (4,867) 663 (5,290) 291 -------
------- ------- ------- Net income (loss) $2,083 $6,352 $4,899
$(16,983) ======= ======= ======= ======= Basic income (loss) per
common share: Income (loss) from continuing operations $0.12 $0.10
$0.18 $(0.30) (Loss) income from discontinued operations (0.08)
0.01 (0.09) 0.01 ------- ------- ------- ------- Net income (loss)
$0.04 $0.11 $0.09 $(0.29) ======= ======= ======= ======= Diluted
income (loss) per common share: Income (loss) from continuing
operations $0.12 $0.10 $0.17 $(0.30) (Loss) income from
discontinued operations (0.08) 0.01 (0.09) 0.01 ------- -------
------- ------- Net income (loss) $0.04 $0.11 $0.08 $(0.29) =======
======= ======= ======= Weighted-average shares outstanding used in
computing basic and diluted net income (loss) per common share:
Basic 57,675 57,693 57,625 57,664 ======= ======= ======= =======
Diluted 58,632 59,061 58,370 57,664 ======= ======= ======= =======
WEBMD HEALTH CORP. CONSOLIDATED SUPPLEMENTAL FINANCIAL INFORMATION
(In thousands, except per share data, unaudited) Three Months Ended
Six Months Ended June 30, June 30, -------- -------- 2009 2008 2009
2008 ---- ---- ---- ---- Revenue Public portal advertising and
sponsorship $75,992 $64,138 $143,281 $122,865 Private portal
services 22,639 21,866 45,614 43,789 ------- ------- -------
------- $98,631 $86,004 $188,895 $166,654 ======= ======= =======
======= Earnings before interest, taxes, non-cash and other items
("Adjusted EBITDA") (a) $23,218 $18,392 $41,906 $34,724 -------
------- ------- ------- Adjusted EBITDA per basic common share
$0.40 $0.32 $0.73 $0.60 ------- ------- ------- ------- Adjusted
EBITDA per diluted common share $0.40 $0.31 $0.72 $0.60 -------
------- ------- ------- Interest, taxes, non-cash and other items
(b) Interest income 924 2,350 1,899 5,803 Depreciation and
amortization (6,804) (7,087) (13,741) (13,759) Non-cash advertising
- - (1,753) (1,558) Non-cash stock-based compensation (5,752)
(3,465) (11,275) (7,145) Impairment of auction rate securities - -
- (27,406) Income tax provision (4,636) (4,501) (6,847) (7,933)
------- ------- ------- ------- Income (loss) from continuing
operations 6,950 5,689 10,189 (17,274) (Loss) income from
discontinued operations, net of tax (4,867) 663 (5,290) 291 -------
------- ------- ------- Net income (loss) $2,083 $6,352 $4,899
$(16,983) ======= ======= ======= ======= Basic income (loss) per
common share: Income (loss) from continuing operations $0.12 $0.10
$0.18 $(0.30) (Loss) income from discontinued operations (0.08)
0.01 (0.09) 0.01 ------- ------- ------- ------- Net income (loss)
$0.04 $0.11 $0.09 $(0.29) ======= ======= ======= ======= Diluted
income (loss) per common share: Income (loss) from continuing
operations $0.12 $0.10 $0.17 $(0.30) (Loss) income from
discontinued operations (0.08) 0.01 (0.09) 0.01 ------- -------
------- ------- Net income (loss) $0.04 $0.11 $0.08 $(0.29) =======
======= ======= ======= Weighted-average shares outstanding used in
computing per share amounts: Basic 57,675 57,693 57,625 57,664
======= ======= ======= ======= Diluted 58,632 59,061 58,370 57,664
======= ======= ======= ======= (a) See Annex A - Explanation of
Non-GAAP Financial Measures (b) Reconciliation of Adjusted EBITDA
to net income (loss) WEBMD HEALTH CORP. CONDENSED CONSOLIDATED
BALANCE SHEETS (In thousands, unaudited) June 30, 2009 December 31,
2008 ------------- ----------------- ASSETS Current assets: Cash
and cash equivalents $246,878 $191,659 Accounts receivable, net
78,674 93,082 Current portion of prepaid advertising - 1,753 Other
current assets 11,147 11,358 Assets of discontinued operations
5,111 12,575 ----- ------ Total current assets 341,810 310,427
Investments 126,330 133,563 Property and equipment, net 54,513
54,165 Goodwill 208,967 208,967 Intangible assets, net 22,878
26,237 Other assets 17,956 22,573 ------ ------ $772,454 $755,932
======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current
liabilities: Accrued expenses $29,273 $31,241 Deferred revenue
86,261 79,613 Due to HLTH 736 427 Liabilities of discontinued
operations 792 2,599 --- ----- Total current liabilities 117,062
113,880 Other long-term liabilities 7,803 8,334 Stockholders'
equity 647,589 633,718 ------- ------- $772,454 $755,932 ========
======== WEBMD HEALTH CORP. CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited) Six Months Ended June 30,
----------------- 2009 2008 ------- ------- Cash flows from
operating activities: Net income (loss) $4,899 $(16,983)
Adjustments to reconcile net income (loss) to net cash provided by
operating activities: Loss (income) from discontinued operations,
net of tax 5,290 (291) Depreciation and amortization 13,741 13,759
Non-cash advertising 1,753 1,558 Non-cash stock-based compensation
11,275 7,145 Deferred and other income taxes 6,545 6,568 Impairment
of auction rate securities - 27,406 Changes in operating assets and
liabilities: Accounts receivable 14,408 15,249 Other assets (1,139)
(1,393) Accrued expenses and other long-term liabilities (2,499)
(5,056) Due to HLTH 309 1,246 Deferred revenue 6,648 10,195 -------
------- Net cash provided by continuing operations 61,230 59,403
Net cash provided by discontinued operations 506 3,355 -------
------- Net cash provided by operating activities 61,736 62,758
Cash flows from investing activities: Proceeds from maturities and
sales of available-for-sale securities 900 41,300 Purchases of
available-for-sale securities - (127,900) Purchases of property and
equipment (10,833) (6,906) Cash received from sale of business, net
of fees 250 1,133 ------- ------- Net cash used in continuing
operations (9,683) (92,373) Net cash used in discontinued
operations (7) (40) ------- ------- Net cash used in investing
activities (9,690) (92,413) Cash flows from financing activities:
Proceeds from issuance of common stock 3,173 2,392 ------- -------
Net cash provided by financing activities 3,173 2,392 Net increase
(decrease) in cash and cash equivalents 55,219 (27,263) Cash and
cash equivalents at beginning of period 191,659 213,753 -------
------- Cash and cash equivalents at end of period $246,878
$186,490 ======= ======= FINANCIAL GUIDANCE SUMMARY WEBMD HEALTH
CORP. 2009 Financial Guidance (in millions, except per share
amounts) Year Ending December 31, 2009 Range (c) --------- Revenue
$420.0 $440.0 ======= ======= Earnings before interest, taxes, non-
cash and other items ("Adjusted EBITDA") (a) $110.0 $120.0 Adjusted
EBITDA per diluted common share $1.77 $1.94 ------- -------
Interest, taxes, non-cash and other items (b) Interest income 4.0
4.0 Depreciation and amortization (33.0) (30.0) Non-cash
advertising (1.8) (1.8) Non-cash stock-based compensation (26.0)
(23.0) Impairment of auction rate securities - - Restructuring - -
Income tax provision (21.8) (28.4) ------- ------- Income from
continuing operations $31.4 $40.8 ======= ======= Income from
continuing operations per common share: Basic $0.53 $0.69 =======
======= Diluted $0.51 $0.66 ======= ======= Weighted-average shares
outstanding used in computing income from continuing operations per
common share: Basic 59.0 59.0 Diluted 62.0 62.0 (a) See Annex A -
Explanation of Non-GAAP Financial Measures. (b) Reconciliation of
Adjusted EBITDA to income from continuing operations. (c) The
guidance for the year ending December 31, 2009 has been adjusted to
exclude the discontinued operations of the Little Blue Book print
directory business. Additional information regarding guidance for
third quarter of 2009: - Revenue is forecasted to be approximately
$109 to $112 in the quarter ending September 30, 2009 - Adjusted
EBITDA as a percentage of revenue is forecasted to be approximately
28% in the quarter ending September 30, 2009 - Income from
continuing operations as a percentage of revenue is forecasted to
be approximately 10% in the quarter ending September 30, 2009
Additional information regarding full year guidance: - Income tax
rate for 2009 is forecasted to be approximately 41% of pretax
income. The income tax provision excludes any benefit relating to
any reversal in 2009 of the valuation allowance against deferred
tax assets. - The distribution of the annual revenue is expected to
be approximately 78.5% public portal advertising and sponsorship
and 21.5% private portal services. Quarterly revenue distributions
may vary from this annual estimate. - Excludes the impact of the
pending merger of WebMD and HLTH. ANNEX A Explanation of Non-GAAP
Financial Measures (All dollar amounts in thousands) The
accompanying WebMD Health Corp. press release and financial tables
include both financial measures in accordance with U.S. generally
accepted accounting principles, or GAAP, as well as non-GAAP
financial measures. The non-GAAP financial measures represent
earnings before interest, taxes, non-cash and other items (which we
refer to as "Adjusted EBITDA") and related per share amounts.
Adjusted EBITDA should be viewed as supplemental to, and not as an
alternative for, "income (loss) from continuing operations" or "net
income (loss)" calculated in accordance with GAAP. The tables
attached to the accompanying press release include reconciliations
of non-GAAP financial measures to GAAP financial measures. Adjusted
EBITDA is used by WebMD's management as an additional measure of
WebMD's performance for purposes of business decision-making,
including developing budgets, managing expenditures, and evaluating
potential acquisitions or divestitures. Period-to-period
comparisons of Adjusted EBITDA help WebMD's management identify
additional trends in WebMD's financial results that may not be
shown solely by period-to-period comparisons of income (loss) from
continuing operations or net income (loss). In addition, WebMD uses
Adjusted EBITDA in the incentive compensation programs applicable
to many of its employees in order to evaluate WebMD's performance.
WebMD management recognizes that Adjusted EBITDA has inherent
limitations because of the excluded items, particularly those items
that are recurring in nature. In order to compensate for those
limitations, management also reviews the specific items that are
excluded from Adjusted EBITDA, but included in income (loss) from
continuing operations or net income (loss), as well as trends in
those items. The amounts of those items are set forth, for the
applicable periods, in the reconciliations of Adjusted EBITDA to
income (loss) from continuing operations or to net income (loss)
that accompany our press releases containing non-GAAP financial
measures, including the reconciliations contained in the tables
attached to the accompanying press release. WebMD believes that the
presentation of Adjusted EBITDA is useful to investors in their
analysis of WebMD's results for reasons similar to the reasons why
WebMD's management finds it useful and because it helps facilitate
investor understanding of decisions made by WebMD's management in
light of the performance metrics used in making those decisions. In
addition, as more fully described below, WebMD believes that
providing Adjusted EBITDA, together with a reconciliation of
Adjusted EBITDA to income (loss) from continuing operations or to
net income (loss), helps investors make comparisons between WebMD
and other companies that may have different capital structures,
different effective income tax rates and tax attributes, different
capitalized asset values and/or different forms of employee
compensation. However, Adjusted EBITDA is intended to provide a
supplemental way of comparing WebMD with other public companies and
is not intended as a substitute for comparisons based on "income
(loss) from continuing operations" or "net income (loss)"
calculated in accordance with GAAP. In making any comparisons to
other companies, investors need to be aware that companies use
different non-GAAP measures to evaluate their financial
performance. Investors should pay close attention to the specific
definition being used and to the reconciliation between such
measures and the corresponding GAAP measures provided by each
company under applicable SEC rules. The following is an explanation
of the items excluded by WebMD from Adjusted EBITDA but included in
income (loss) from continuing operations: -- Depreciation and
Amortization. Depreciation and amortization expense is a non-cash
expense relating to capital expenditures and intangible assets
arising from acquisitions that are expensed on a straight-line
basis over the estimated useful life of the related assets. WebMD
excludes depreciation and amortization expense from Adjusted EBITDA
because it believes (i) the amount of such expenses in any specific
period may not directly correlate to the underlying performance of
WebMD's business operations and (ii) such expenses can vary
significantly between periods as a result of new acquisitions and
full amortization of previously acquired tangible and intangible
assets. Accordingly, WebMD believes this exclusion assists
management and investors in making period-to-period comparisons of
operating performance. Investors should note that use of tangible
and intangible assets contributed to revenue in the periods
presented and will contribute to future revenue generation and
should also note that such expenses will recur in future periods --
Stock-Based Compensation Expense. Stock-based compensation expense
is a non-cash expense arising from the grant of stock-based awards
to employees. WebMD believes that excluding the effect of
stock-based compensation from Adjusted EBITDA assists management
and investors in making period-to-period comparisons in its
operating performance because it believes (i) the amount of such
expenses in any specific period may not directly correlate to the
underlying performance of WebMD's business operations and (ii) such
expenses can vary significantly between periods as a result of the
timing of grants of new stock-based awards, including grants in
connection with acquisitions. Additionally, WebMD believes that
excluding stock-based compensation from Adjusted EBITDA assists
management and investors in making meaningful comparisons between
WebMD's operating performance and the operating performance of
other companies that may use different forms of employee
compensation or different valuation methodologies for their
stock-based compensation. Investors should note that stock-based
compensation is a key incentive offered to employees whose efforts
contributed to the operating results in the periods presented and
are expected to contribute to operating results in future periods.
Investors should also note that such expenses will recur in the
future. Stock-based compensation expenses included in the Statement
of Operations are summarized as follows: Three Months Ended Six
Months Ended June 30, June 30, 2009 2008 2009 2008 Non-cash
stock-based compensation included in: Cost of operations $(1,555)
$(817) $(3,178) $(1,933) Sales and marketing $(2,001) $(1,261)
$(3,551) $(2,387) General and administrative $(2,196) $(1,387)
$(4,546) $(2,825) (Loss) income from discontinued operations $(43)
$(23) $(174) $(55) -- Non-Cash Advertising Expense. This expense
relates to the usage of non-cash advertising obtained from News
Corporation ("Newscorp") in exchange for equity securities issued
by our parent, HLTH Corporation in 2000. The advertising was
available only on various Newscorp properties, primarily its
television network and cable channels, without any cash cost to
WebMD and expired this year. WebMD excludes this expense from
Adjusted EBITDA (i) because it is a non-cash expense, (ii) because
it is incremental to other non-television cash advertising expense
that WebMD otherwise incurs and (iii) to assist management and
investors in comparing its operating results over multiple periods.
Investors should note that it is likely that WebMD derives some
benefit from such advertising. Non-cash advertising expenses
included in the Consolidated Statement of Operations in Sales and
Marketing expense were $1,753 and $1,558 for the six months ended
June 30, 2009 and 2008, respectively. There were no non-cash
advertising expenses for the three months ended June 30, 2009 and
2008. -- Interest Income. Interest income is associated with the
level of marketable debt securities and other interest bearing
accounts in which WebMD invests. Interest income varies over time
due to varying levels of securities available for investment.
Transactions that WebMD has entered into in recent periods that
have impacted securities available for investment include the
initial public offering of equity in WebMD and acquisitions of
other companies for varying amounts of cash since our initial
public offering. Additional financing transactions as well as
potential acquisitions that WebMD may enter into in the future
could impact the levels and timing of securities available for
investment. WebMD excludes interest income from Adjusted EBITDA (i)
because it is not directly attributable to the performance of
WebMD's business operations and, accordingly, its exclusion assists
management and investors in making period-to-period comparisons of
operating performance and (ii) to assist management and investors
in making comparisons to companies with different capital
structures. Investors should note that interest income will recur
in future periods. -- Income Tax Provision (Benefit). WebMD
maintains a valuation allowance on a portion of its net operating
loss carryforwards, the amount of which may change from quarter to
quarter based on factors that are not directly related to WebMD's
results for the quarter. The valuation allowance is either reversed
through the statement of operations or additional paid-in capital.
The timing of such reversals has not been consistent and as a
result, WebMD's income tax expense can fluctuate significantly from
period to period in a manner not directly related to WebMD's
operating performance. WebMD excludes the income tax provision
(benefit) from Adjusted EBITDA (i) because it believes that the
income tax provision (benefit) is not directly attributable to the
underlying performance of WebMD's business operations and,
accordingly, its exclusion assists management and investors in
making period-to-period comparisons of operating performance and
(ii) to assist management and investors in making comparisons to
companies with different tax attributes. Investors should note that
income tax provision (benefit) will recur in future periods. --
Other Items. WebMD engages in other activities and transactions
that can impact WebMD's overall income (loss) from continuing
operations. WebMD excludes these other items from Adjusted EBITDA
when it believes these activities or transactions are not directly
attributable to the performance of WebMD's business operations and,
accordingly, their exclusion assists management and investors in
making period-to-period comparisons of operating performance.
Investors should note that these other items may recur in future
periods. In the accompanying press release and financial tables,
WebMD has excluded loss on the impairment of auction rate
securities from Adjusted EBITDA. DATASOURCE: WebMD CONTACT:
Investors, Risa Fisher, , +1-212-624-3817, or Media, Kate Hahn, ,
+1-212-624-3760 Web Site: http://www.webmd.com/
Copyright